Cited by 241Peripheral Artery Disease ManagementNitric Oxide and Endothelin EffectsCardiovascular Health and Disease Prevention

l -Arginine Supplementation in Peripheral Arterial Disease: No Benefit and Possible Harm

Wilson, Andrew M., Harada, Randall, Nair, Nandini, Balasubramanian, Naras, Cooke, John P.·2007·Circulation

Abstract

Background— l -Arginine is the precursor of endothelium-derived nitric oxide, an endogenous vasodilator. l -Arginine supplementation improves vascular reactivity and functional capacity in peripheral arterial disease (PAD) in small, short-term studies. We aimed to determine the effects of long-term administration of l -arginine on vascular reactivity and functional capacity in patients with PAD. Methods and Results— The Nitric Oxide in Peripheral Arterial Insufficiency (NO-PAIN) study was a randomized clinical trial of oral l -arginine (3 g/d) versus placebo for 6 months in 133 subjects with intermittent claudication due to PAD in a single-center setting. The primary end point was the change at 6 months in the absolute claudication distance as assessed by the Skinner-Gardner treadmill protocol. l -Arginine supplementation significantly increased plasma l -arginine levels. However, measures of nitric oxide availability (including flow-mediated vasodilation, vascular compliance, plasma and urinary nitrogen oxides, and plasma citrulline formation) were reduced or not improved compared with placebo. Although absolute claudication distance improved in both l -arginine- and placebo-treated patients, the improvement in the l -arginine-treated group was significantly less than that in the placebo group (28.3% versus 11.5%; P =0.024). Conclusions— In patients with PAD, long-term administration of l -arginine does not increase nitric oxide synthesis or improve vascular reactivity. Furthermore, the expected placebo effect observed in studies of functional capacity was attenuated in the l -arginine-treated group. As opposed to its short-term administration, long-term administration of l -arginine is not useful in patients with intermittent claudication and PAD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.106.683656

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • ADMA was recognized as an important marker for cardiovascular disease progression soon after its discovery in cells and tissue.

    “Soon after its discovery in cells and tissue, ADMA was recognized as an important marker for cardiovascular disease progression (656, 829, 961, 1011, 1053, 1068).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [5]5. infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. JAMA . 2006;295:58-64.

Cited by

Sorted by citations

Authors
Wilson, A. M., Harada, R., Nair, N., Balasubramanian, N., & Cooke, J. P.
Affiliations
Stanford Medicine (US)
Venue
Circulation
Published
2007-07-10
Volume
116
Issue
2
Pages
188-195
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2000796869
Cited by
241
References
48
Citations by year
2026: 7 · 2025: 11 · 2024: 4 · 2023: 5 · 2022: 9 · 2021: 7 · 2020: 14 · 2019: 9 · 2018: 11 · 2017: 24 · 2016: 15 · 2015: 13 · 2014: 13 · 2013: 12 · 2012: 26
FWCI
16.26
Type
journal article
Language
en
Open access
closed
Locations
  • Circulation (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Royal Australasian College of Physicians
  • National Health and Medical Research Council
  • National Medical Research Council
  • National Heart, Lung, and Blood Institute (R01 HL-63685, R01HL075774, T32HL007708, R01HL063685, P50HL083800)
  • National Institute of Allergy and Infectious Diseases (P01AI050153, P01AI50153)
  • NIH Clinical Center
Topics
  • Health Sciences › Medicine › Surgery › Peripheral Artery Disease Management
  • Health Sciences › Medicine › Physiology › Nitric Oxide and Endothelin Effects
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
Keywords
arginine supplementation, peripheral arterial disease, intermittent claudication, nitric oxide, endothelial function, flow-mediated dilation, vascular compliance, citrulline, claudication distance, long-term supplementation, placebo effect
MeSH terms
Aged, Arginine, Brachial Artery, Female, Humans, Intermittent Claudication, Male, Middle Aged, Placebos, Prospective Studies, Peripheral Vascular Diseases, Patient Selection, Nitric Oxide Synthase, Dietary Supplements, Racial Groups

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review